Thomas C. Hanff
( out of 15 reviews )

Thomas C. Hanff, MD, MSCE, MPH

Languages spoken: English

Clinical Locations

Saint Alphonsus Regional Medical Center

Boise
208-367-2121

University of Utah Hospital

Heart Failure Clinic
Salt Lake City
801-585-5122

University of Utah Hospital

Cardiovascular Center
Salt Lake City
801-585-5122

Veterans Administration Medical Center

Salt Lake City
801-584-1235

  • Dr. Thomas Hanff is an Assistant Professor of Medicine at the University of Utah and the Salt Lake VA Medical Center. Dr. Hanff graduated Summa Cum Laude from the University of California, Los Angeles with a major in Neuroscience and a minor in Public Policy (2008). He received his medical degree and Master of Public Health from the Johns Hopkins University Schools of Medicine and Public Health (2013). He then trained at the University of Pennsylvania where he completed internship and residency in Internal Medicine (2016) and fellowships in Cardiovascular Disease (2019) and Advanced Heart Failure and Transplant Cardiology (2021). He also completed a Master of Science in Clinical Epidemiology while at the University of Pennsylvania (2020). He joined the faculty at the University of Utah, Division of Cardiovascular Medicine in 2021.

    Dr. Hanff specializes in the care of patients with advanced heart failure of all types, both in the hospital and in the outpatient setting. He has extensive expertise in the management of patients who require advanced heart failure therapies such as left ventricular assist devices, heart transplantation, or inotropic therapy. He also specializes in the care of patients with acute decompensated heart failure or cardiogenic shock and in the use of temporary mechanical circulatory support devices as a bridge to recovery or more definitive therapy. He strives to practice at the forefront of evidence-based medicine, with personalized therapeutic plans for every patient matched to their underlying illness and goals of care.

    Dr. Hanff’s research is motivated by two simple questions: 1) Which patients would benefit from various advanced heart failure therapies and 2) When is the optimal time to offer each therapy to a patient based on their individual characteristics? To answer these questions, Dr. Hanff has developed a research program that couples traditional outcomes research with personalized “omics” approaches, using advanced statistical modeling techniques, bioinformatics, and machine learning. He collaborates with several highly regarded researchers throughout the world and works closely with numerous landmark national and international cohorts. His work has been published in top medical journals including JAMA Cardiology, Circulation Heart Failure, Lancet Respiratory Medicine, the Journal of Heart and Lung Transplantation, JACC: Basic to Translational Science, Hypertension, and Stroke.

    Dr. Hanff is board certified in Internal Medicine, Cardiovascular Medicine, and Echocardiography. He is involved with numerous professional societies including the International Society for Heart and Lung Transplantation, the American Heart Association, the Heart Failure Society of America, and the American College of Cardiology, for which he has served on the Clinical Data Standards Task Force.

    Specialties

    Board Certification

    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Advanced Heart Failure & Transplant Cardiology)
    American Board of Internal Medicine (Sub: Cardiovascular Disease)
    National Board of Echocardiography
    National Board of Medical Examiners

    Patient Rating

    4.6 /5
    ( out of 15 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    August 21, 2023
    EXTERNAL SITE

    Thank you Dr. Hanff, I was concerned that I didn't get to see Dr. Pinzar, but you alleviated my fear and were a wonderful provider. Your care and concern for me as a patient was stellar!!!!

    August 12, 2023
    EXTERNAL SITE

    Professional with care Committed to connecting with the patient. Clear on every Option and approach. Committed to improve my heart function overall. You can tell he really cares, very devoted to the care of his patients Healthiest outcome. Communicated with me where I could follow along with what he was saying and I left there with a clear understanding of what was held. My head up high because I walked in there with very little hope. I left with joy in my heart. Smiling, I'm looking forward Now to a better heart function and a Lively, Active Future

    March 02, 2023
    UH HOSPITALS AND CLINICS

    I have had problems in the past he just does nothing to help . I am tired of working with him!!!!!

  • Dr. Thomas Hanff is an Assistant Professor of Medicine at the University of Utah and the Salt Lake VA Medical Center. Dr. Hanff graduated Summa Cum Laude from the University of California, Los Angeles with a major in Neuroscience and a minor in Public Policy (2008). He received his medical degree and Master of Public Health from the Johns Hopkins University Schools of Medicine and Public Health (2013). He then trained at the University of Pennsylvania where he completed internship and residency in Internal Medicine (2016) and fellowships in Cardiovascular Disease (2019) and Advanced Heart Failure and Transplant Cardiology (2021). He also completed a Master of Science in Clinical Epidemiology while at the University of Pennsylvania (2020). He joined the faculty at the University of Utah, Division of Cardiovascular Medicine in 2021.

    Dr. Hanff specializes in the care of patients with advanced heart failure of all types, both in the hospital and in the outpatient setting. He has extensive expertise in the management of patients who require advanced heart failure therapies such as left ventricular assist devices, heart transplantation, or inotropic therapy. He also specializes in the care of patients with acute decompensated heart failure or cardiogenic shock and in the use of temporary mechanical circulatory support devices as a bridge to recovery or more definitive therapy. He strives to practice at the forefront of evidence-based medicine, with personalized therapeutic plans for every patient matched to their underlying illness and goals of care.

    Dr. Hanff’s research is motivated by two simple questions: 1) Which patients would benefit from various advanced heart failure therapies and 2) When is the optimal time to offer each therapy to a patient based on their individual characteristics? To answer these questions, Dr. Hanff has developed a research program that couples traditional outcomes research with personalized “omics” approaches, using advanced statistical modeling techniques, bioinformatics, and machine learning. He collaborates with several highly regarded researchers throughout the world and works closely with numerous landmark national and international cohorts. His work has been published in top medical journals including JAMA Cardiology, Circulation Heart Failure, Lancet Respiratory Medicine, the Journal of Heart and Lung Transplantation, JACC: Basic to Translational Science, Hypertension, and Stroke.

    Dr. Hanff is board certified in Internal Medicine, Cardiovascular Medicine, and Echocardiography. He is involved with numerous professional societies including the International Society for Heart and Lung Transplantation, the American Heart Association, the Heart Failure Society of America, and the American College of Cardiology, for which he has served on the Clinical Data Standards Task Force.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Primary
    Academic Divisions Cardiovascular Medicine
    Board Certification
    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Advanced Heart Failure & Transplant Cardiology)
    American Board of Internal Medicine (Sub: Cardiovascular Disease)
    National Board of Echocardiography
    National Board of Medical Examiners

    Education history

    Fellowship Advanced Heart Failure and Transplant Cardiology - University of Pennsylvania Fellow
    Clinical Epidemiology - University of Pennsylvania Department of Biostatistics, Epidemiology, and Informatics M.S.C.E
    Fellowship Cardiology - University of Pennsylvania Fellow
    Medicine - University of Pennsylvania Resident
    Internship Medicine - University of Pennsylvania Intern
    Master of Public Health - Johns Hopkins Bloomberg School of Public Health M.P.H.
    Professional Medical Medicine - Johns Hopkins University School of Medicine M.D.
    Neuroscience - University of California, Los Angeles B.S.

    Selected Publications

    Journal Article

    1. Sideris K, Weir CR, Schmalfuss C, Hanson H, Pipke M, Tseng PH, Lewis N, Sallam K, Bozkurt B, Hanff T, Schofield R, Larimer K, Kyriakopoulos CP, Taleb I, Brinker L, Curry T, Knecht C, Butler JM, Stehlik J (2023). Artificial intelligence predictive analytics in heart failure: results of the pilot phase of a pragmatic randomized clinical trial. J Am Med Inform Assoc, 31(4), 919-928. (Read full article)
    2. Taleb I, Kyriakopoulos CP, Fong R, Ijaz N, Demertzis Z, Sideris K, Wever-Pinzon O, Koliopoulou AG, Bonios MJ, Shad R, Peruri A, Hanff TC, Dranow E, Giannouchos TV, Krauspe E, Zakka C, Tang DG, Nemeh HW, Stehlik J, Fang JC, Selzman CH, Alharethi R, Caine WT, Cowger JA, Hiesinger W, Shah P, Drakos SG (2025). Machine Learning Multicenter Risk Model to Predict Right Ventricular Failure After Mechanical Circulatory Support: The STOP-RVF Score. JAMA Cardiol, 9(3), 272-282. (Read full article)
    3. Alba AC, Kirklin JK, Cantor RS, Deng L, Ross HJ, Jacobs JP, Rao V, Hanff TC, Stehlik J (2023). The impact of obesity and LVAD-bridging on heart transplant candidate outcomes: a linked STS INTERMACS - OPTN/UNOS data analysis. J Heart Lung Transplant, 42(11), 1587-1596. (Read full article)
    4. Schurr JW, Sigal I, Usman A, Patel P, Lefebvre B, Kurcik K, Atluri P, Acker M, Bermudez C, Rame JE, Hanff T, Cevasco M, Wald J (2023). Effect of Anesthesia Induction on Cardiac Hemodynamics in Patients Undergoing Durable Left Ventricular Assist Device Implantation: The EACH-LVAD Study. ASAIO J, 69(10), 907-914. (Read full article)
    5. Dalia T, Pothuru S, Chan WC, Mehta H, Goyal A, Farhoud H, Boda I, Malhotra A, Vidic A, Rali AS, Hanff TC, Gupta K, Fang JC, Shah Z (2023). Trends and Outcomes of Cardiogenic Shock in Patients With End-Stage Renal Disease: Insights From USRDS Database. Circ Heart Fail, 16(8), e010462. (Read full article)
    6. Kyriakopoulos CP, Horne BD, Sideris K, Taleb I, Griffin RJ, Sheffield E, Alharethi R, Hanff TC, Stehlik J, Selzman CH, Drakos SG (2023). Left ventricular functional improvement appears to contribute to lower rates of device thrombosis in patients on durable mechanical circulatory support. J Heart Lung Transplant, 42(7), 853-858. (Read full article)
    7. Gard EK, Beale AL, Telles F, Silvestry FE, Hanff T, Hummel SL, Litwin SE, Petrie MC, Shah SJ, Borlaug BA, Burkhoff D, Komtebedde J, Kaye DM, Nanayakkara S (2023). Left atrial enlargement is associated with pulmonary vascular disease in heart failure with preserved ejection fraction. Eur J Heart Fail, 25(6), 806-814. (Read full article)
    8. Zhang RS, Hanff TC, Zhang Y, Genuardi MV, Peters CJ, Levin A, Molina M, McLean RC, Mazurek JA, Zamani P, Tanna MS, Wald J, Santangeli P, Atluri P, Goldberg LR, Birati EY (2023). Chronotropic Incompetence after Heart Transplantation Is Associated with Increased Mortality and Decreased Functional Capacity. J Clin Med, 12(10). (Read full article)
    9. Peters CJ, Zhang RS, Vidula MK, Giri J, Atluri P, Acker MA, Bermdez CA, Levin A, Urgo K, Wald J, Mazurek JA, Hanff TC, Goldberg LR, Jagasia D, Birati EY (2023). Durable Left Ventricular Assist Device Outflow Graft Obstructions: Clinical Characteristics and Outcomes. J Clin Med, 12(6). (Read full article)
    10. Hanff TC, Browne A, Dickey J, Gaines H, Harhay MO, Goodwin M, Selzman CH, Fang JC, Drakos SG, Stehlik J (2022). Heart waitlist survival in adults with an intra-aortic balloon pump relative to other Status 2, Status 1, and inotrope Status 3 patients. J Heart Lung Transplant, 42(3), 368-376. (Read full article)
    11. Drakos SG, Badolia R, Makaju A, Kyriakopoulos CP, Wever-Pinzon O, Tracy CM, Bakhtina A, Bia R, Parnell T, Taleb I, Ramadurai DKA, Navankasattusas S, Dranow E, Hanff TC, Tseliou E, Shankar TS, Visker J, Hamouche R, Stauder EL, Caine WT, Alharethi R, Selzman CH, Franklin S (2022). Distinct Transcriptomic and Proteomic Profile Specifies Patients Who Have Heart Failure With Potential of Myocardial Recovery on Mechanical Unloading and Circulatory Support. Circulation, 147(5), 409-424. (Read full article)
    12. Hanff TC, Zhang Y, Zhang RS, Genuardi MV, Molina M, McLean RC, Mazurek JA, Tanna MS, Wald JW, Atluri P, Acker MA, Goldberg LR, Zamani P, Birati EY (2023). Early Cardiopulmonary Fitness after Heart Transplantation as a Determinant of Post-Transplant Survival. J Clin Med, 12(1). (Read full article)
    13. Browne A, Gaines H, Alharethi R, Goodwin M, Selzman CH, Fang JC, Drakos SG, Stehlik J, Hanff TC (2022). Interrupted Time Series Analysis of Donor Heart Use Before and After the 2018 UNOS Heart Allocation Policy Change. J Card Fail, 29(2), 220-224. (Read full article)
    14. Cohen JB, Mitchell GF, Gill D, Burgess S, Rahman M, Hanff TC, Ramachandran VS, Mutalik KM, Townsend RR, Chirinos JA (2022). Arterial Stiffness and Diabetes Risk in Framingham Heart Study and UK Biobank. Circ Res, 131(6), 545-554. (Read full article)
    15. Shore S, Hanff TC, Mazurek JA, Fox A, Tanna MS, Grandin EW, Zhang R, Wald J, Peters C, Acker MA, Atluri P, Rame JE, Goldberg LR, Jessup M, Margulies KB, Birati EY (2022). The Anemia Stress Index-Anemia, Transfusions, and Mortality in Patients with Continuous Flow Ventricular Assist Devices. J Clin Med, 11(15). (Read full article)
    16. Peters CJ, Hanff TC, Genuardi MV, Zhang R, Domenico C, Atluri P, Mazurek JA, Urgo K, Wald J, Tanna MS, Shore S, Acker MA, Goldberg LR, Margulies KB, Birati EY (2022). Safety and Effectiveness of Intravenous Iron Therapy in Patients Supported by Durable Left Ventricular Assist Devices. J Clin Med, 11(13). (Read full article)
    17. Sadeh B, Ugolini S, Pinzon OW, Potapov EV, Selzman CH, Bader F, Zuckermann AO, Gomez-Mesa JE, Shah KS, Alharethi R, Morejon-Barragan P, Hanff T, Goldraich LA, Farrero M, MacDonald PS, Drakos S, Mehra MR, Stehlik J (2022). Medical decisions in organ donors and heart transplant candidates with history of COVID-19 infection: An international practice survey. Clin Transplant, 36(7), e14733. (Read full article)
    18. Zhang RS, Hanff TC, Peters CJ, Evans PT, Marble J, Rame JE, Atluri P, Urgo K, Tanna MS, Mazurek JA, Acker MA, Cevasco M, Birati EY, Wald JW (2022). Left Ventricular Assist Device as a Bridge to Recovery: Single Center Experience of Successful Device Explantation. ASAIO J, 68(6), 822-828. (Read full article)
    19. Edelson JB, Edwards JJ, Katcoff H, Mondal A, Chen F, Reza N, Hanff TC, Griffis H, Mazurek JA, Wald J, Burstein DS, Atluri P, OConnor MJ, Goldberg LR, Zamani P, Groeneveld PW, Rossano JW, Lin KY, Birati EY (2022). Novel Risk Model to Predict Emergency Department Associated Mortality for Patients Supported With a Ventricular Assist Device: The Emergency Department-Ventricular Assist Device Risk Score. J Am Heart Assoc, 11(2), e020942. (Read full article)
    20. Zamani P, Proto EA, Wilson N, Fazelinia H, Ding H, Spruce LA, Davila A Jr, Hanff TC, Mazurek JA, Prenner SB, Desjardins B, Margulies KB, Kelly DP, Arany Z, Doulias PT, Elrod JW, Allen ME, McCormack SE, Schur GM, DAquilla K, Kumar D, Thakuri D, Prabhakaran K, Langham MC, Poole DC, Seeholzer SH, Reddy R, Ischiropoulos H, Chirinos JA (2021). Multimodality assessment of heart failure with preserved ejection fraction skeletal muscle reveals differences in the machinery of energy fuel metabolism. ESC Heart Fail, 8(4), 2698-2712. (Read full article)
    21. Genuardi MV, Moss N, Najjar SS, Houston BA, Shore S, Vorovich E, Atluri P, Molina M, Chambers S, Sharkoski T, Hsich E, Estep JD, Owens AT, Alexander KM, Chaudhry SP, Garcia-Cortes R, Molina E, Rodrigo M, Wald MJ, Margulies KB, Hanff TC, Zimmer R, Kilic A, Mclean R, Vidula H, Dodd K, Blumberg EA, Mazurek JA, Goldberg LR, Alvarez-Garcia J, Mancini D, Teuteberg JJ, Tedford RJ, Birati EY (2021). Coronavirus disease 2019 in heart transplant recipients: Risk factors, immunosuppression, and outcomes. J Heart Lung Transplant, 40, 926-935. (Read full article)
    22. Khatana SAM, Hanff TC, Nathan AS, Dayoub EJ, Grandin EW, Rame JE, Fanaroff AC, Giri J, Groeneveld PW (2021). Association of Health Insurance Payer Type and Outcomes After Durable Left Ventricular Assist Device Implantation: An Analysis of the STS-INTERMACS Registry. Circ Heart Fail, 14(5), e008277. (Read full article)
    23. Derington CG, Cohen JB, Mohanty AF, Greene TH, Cook J, Ying J, Wei G, Herrick JS, Stevens VW, Jones BE, Wang L, Zheutlin AR, South AM, Hanff TC, Smith SM, Cooper-DeHoff RM, King JB, Alexander GC, Berlowitz DR, Ahmad FS, Penrod MJ, Hess R, Conroy MB, Fang JC, Rubin MA, Beddhu S, Cheung AK, Xian W, Weintraub WS, Bress AP (2021). Angiotensin II receptor blocker or angiotensin-converting enzyme inhibitor use and COVID-19-related outcomes among US Veterans. PLoS One, 16(4), e0248080. (Read full article)
    24. Birati EY, Najjar SS, Tedford RJ, Houston BA, Shore S, Vorovich E, Atluri P, Urgo K, Molina M, Chambers S, Escobar N, Hsich E, Estep JD, Alexander KM, Teuteberg JJ, Chaudhry SP, Ravichandran A, DeVore AD, Margulies KB, Hanff TC, Zimmer R, Kilic A, Wald JW, Vidula H, Martens J, Blumberg EA, Mazurek JA, Owens AT, Goldberg LR, Alvarez-Garcia J, Mancini DM, Moss N, Genuardi MV (2021). Characteristics and Outcomes of COVID-19 in Patients on Left Ventricular Assist Device Support. Circ Heart Fail, 14(4), e007957. (Read full article)
    25. Cohen JB, Hanff TC, William P, Sweitzer N, Rosado-Santander NR, Medina C, Rodriguez-Mori JE, Renna N, Chang TI, Corrales-Medina V, Andrade-Villanueva JF, Barbagelata A, Cristodulo-Cortez R, Daz-Cucho OA, Spaak J, Alfonso CE, Valdivia-Vega R, Villavicencio-Carranza M, Ayala-Garca RJ, Castro-Callirgos CA, Gonzlez-Hernndez LA, Bernales-Salas EF, Coacalla-Guerra JC, Salinas-Herrera CD, Nicolosi L, Basconcel M, Byrd JB, Sharkoski T, Bendez-Huasasquiche LE, Chittams J, Edmonston DL, Vasquez CR, Chirinos JA (2021). Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial. Lancet Respir Med, 9(3), 275-284. (Read full article)
    26. Edelson JB, Edwards JJ, Katcoff H, Mondal A, Reza N, Hanff TC, Griffis H, Mazurek JA, Wald J, Owens AT, Burstein DS, Atluri P, OConnor MJ, Goldberg LR, Zamani P, Groeneveld PW, Rossano JW, Lin KY, Birati EY (2021). An Increasing Burden of Disease: Emergency Department Visits Among Patients With Ventricular Assist Devices From 2010 to 2017. J Am Heart Assoc, 10(4), e018035. (Read full article)
    27. Hanff TC, Cohen JB, Zhao L, Javaheri A, Zamani P, Prenner SB, Rietzschel E, Jia Y, Walsh A, Maranville J, Wang Z, Adam L, Ramirez-Valle F, Schafer P, Seiffert D, Gordon DA, Cvijic ME, Cappola TP, Chirinos JA (2021). Quantitative Proteomic Analysis of Diabetes Mellitus in Heart Failure With Preserved Ejection Fraction. JACC Basic Transl Sci, 6(2), 89-99. (Read full article)
    28. Hanff TC, Mohareb AM, Giri J, Cohen JB, Chirinos JA (2020). Thrombosis in COVID-19. Am J Hematol, 95(12), 1578-1589. (Read full article)
    29. Shore S, Hanff TC, Mazurek JA, Seigerman M, Zhang R, Grandin EW, Vorovich E, Mather P, Olt C, Howard J, Wald J, Acker MA, Goldberg LR, Atluri P, Margulies KB, Rame JE, Birati EY (2020). The effect of transfusion of blood products on ventricular assist device support outcomes. ESC Heart Fail, 7(6), 3573-3581. (Read full article)
    30. Chirinos JA, Cohen JB, Zhao L, Hanff T, Sweitzer N, Fang J, Corrales-Medina V, Anmar R, Morley M, Zamani P, Bhattacharya P, Brandimarto J, Jia Y, Basso MD, Wang Z, Ebert C, Ramirez-Valle F, Schafer PH, Seiffert D, Gordon DA, Cappola T (2020). Clinical and Proteomic Correlates of Plasma ACE2 (Angiotensin-Converting Enzyme 2) in Human Heart Failure. Hypertension, 76(5), 1526-1536. (Read full article)
    31. Cohen JB, Hanff TC, Corrales-Medina V, William P, Renna N, Rosado-Santander NR, Rodriguez-Mori JE, Spaak J, Andrade-Villanueva J, Chang TI, Barbagelata A, Alfonso CE, Bernales-Salas E, Coacalla J, Castro-Callirgos CA, Tupayachi-Venero KE, Medina C, Valdivia R, Villavicencio M, Vasquez CR, Harhay MO, Chittams J, Sharkoski T, Byrd JB, Edmonston DL, Sweitzer N, Chirinos JA (2020). Randomized elimination and prolongation of ACE inhibitors and ARBs in coronavirus 2019 (REPLACE COVID) Trial Protocol. J Clin Hypertens (Greenwich), 22(10), 1780-1788. (Read full article)
    32. Hanff TC, Harhay MO, Brown TS, Cohen JB, Mohareb AM (2020). Is There an Association Between COVID-19 Mortality and the Renin-Angiotensin System? A Call for Epidemiologic Investigations. Clin Infect Dis, 71(15), 870-874. (Read full article)
    33. Cohen JB, Hanff TC, Bress AP, South AM (2020). Relationship Between ACE2 and Other Components of the Renin-Angiotensin System. Curr Hypertens Rep, 22(7), 44. (Read full article)
    34. Hanff TC, Harhay MO, Kimmel SE, Molina M, Mazurek JA, Goldberg LR, Birati EY (2020). Trends in Mechanical Support Use as a Bridge to Adult Heart Transplant Under New Allocation Rules. JAMA Cardiol, 5(6), 728-729. (Read full article)
    35. Hanff TC, Kaye DM, Hayward CS, Post MC, Malek F, Hasenfu G, Gustafsson F, Burkhoff D, Shah SJ, Litwin SE, Kahwash R, Hummel SL, Borlaug BA, Solomon SD, Lam CSP, Komtebedde J, Silvestry FE, REDUCE LAP-HF study investigators and research staff (2019). Assessment of Predictors of Left Atrial Volume Response to a Transcatheter InterAtrial Shunt Device (from the REDUCE LAP-HF Trial). Am J Cardiol, 124(12), 1912-1917. (Read full article)
    36. Birati EY, Hanff TC, Maldonado D, Grandin EW, Kennel PJ, Mazurek JA, Vorovich E, Seigerman M, Howard JLL, Acker MA, Naka Y, Wald J, Goldberg LR, Jessup M, Atluri P, Margulies KB, Schulze PC, Rame JE (2018). Predicting Long Term Outcome in Patients Treated With Continuous Flow Left Ventricular Assist Device: The Penn-Columbia Risk Score. J Am Heart Assoc, 7(6). (Read full article)
    37. Gopal DJ, Hanff TC, Mazurek JA, Grandin WE, Howard J, Forde-McLean R, Wald J, King K, Acker MA, Goldberg LR, Jessup M, Atluri P, Margulies KB, Rame EJ, Birati EY (2017). Prognostic Implications of Changes in Albumin Following Left Ventricular Assist Device Implantation in Patients With Severe Heart Failure. Am J Cardiol, 120(11), 2003-2007. (Read full article)
    38. Birati EY, Mathelier H, Molina M, Hanff TC, Mazurek JA, Atluri P, Acker MA, Rame JE, Margulies KB, Goldberg LR, Jessup M (2016). Comparison of Causes of Death After Heart Transplantation in Patients With Left Ventricular Ejection Fractions ≤35% Versus >35. Am J Cardiol, 117(8), 1322-6. (Read full article)
    39. Golbus JR, Manly DA, Wonneberger KA, Hanff TC, Murphy KM, Wang DS, McKee SG, Bellini L (2015). Implementation of a Novel, Resident-Led, Nocturnal Curriculum. J Grad Med Educ, 7(3), 417-21. (Read full article)
    40. Minor TR, Hanff TC (2015). Adenosine signaling in reserpine-induced depression in rats. Behav Brain Res, 286, 184-91. (Read full article)
    41. Hanff TC, Sharrett AR, Mosley TH, Shibata D, Knopman DS, Klein R, Klein BE, Gottesman RF (2014). Retinal microvascular abnormalities predict progression of brain microvascular disease: an atherosclerosis risk in communities magnetic resonance imaging study. Stroke, 45(4), 1012-7. (Read full article)
    42. Gill RS, Hambridge HL, Schneider EB, Hanff T, Tamargo RJ, Nyquist P (2012). Falling temperature and colder weather are associated with an increased risk of aneurysmal subarachnoid hemorrhage. World Neurosurg, 79(1), 136-42. (Read full article)
    43. Hanff TC, Furst SJ, Minor TR (2010). Biochemical and anatomical substrates of depression and sickness behavior. Isr J Psychiatry Relat Sci, 47(1), 64-71. (Read full article)

    Review

    1. Lim HS, Gonzlez-Costello J, Belohlavek J, Zweck E, Blumer V, Schrage B, Hanff TC (2024). Hemodynamic management of cardiogenic shock in the intensive care unit. [Review]. J Heart Lung Transplant. (Read full article)
    2. Barnett CF, Brusca SB, Hanff TC, Blumer V, Kalif A, Kanwar M (2023). Management of Cardiogenic Shock Unrelated to Acute Myocardial Infarction. [Review]. Can J Cardiol, 39(4), 406-419. (Read full article)
    3. Tehrani BN, Drakos SG, Billia F, Batchelor WB, Luk A, Stelling K, Tonna J, Rosner C, Hanff T, Rao V, Brozzi NA, Baran DA (2022). The Multicenter Collaborative to Enhance Biologic Understanding, Quality, and Outcomes in Cardiogenic Shock (VANQUISH Shock): Rationale and Design. [Review]. Can J Cardiol, 38(8), 1286-1295. (Read full article)
    4. Siripanthong B, Asatryan B, Hanff TC, Chatha SR, Khanji MY, Ricci F, Muser D, Ferrari VA, Nazarian S, Santangeli P, Deo R, Cooper LT Jr, Mohiddin SA, Chahal CAA (2022). The Pathogenesis and Long-Term Consequences of COVID-19 Cardiac Injury. [Review]. JACC Basic Transl Sci, 7(3), 294-308. (Read full article)

    Conference Proceedings

    1. Kanwar MK, Billia F, Randhawa V, Cowger JA, Barnett CM, Chih S, Ensminger S, Hernandez-Montfort J, Sinha SS, Vorovich E, Proudfoot A, Lim HS, Blumer V, Jennings DL, Reshad Garan A, Renedo MF, Hanff TC, Baran DA, Consensus Conference participants (2023). Heart failure related cardiogenic shock: An ISHLT consensus conference content summary. J Heart Lung Transplant, United States, 43(2), 189-203. (Read full article)

    Editorial

    1. Stehlik J, Cherikh WS, Hanff TC (2022). The HeartMate 3 Risk Score: Updating LVAD Risk Assessment for the Current Era. JACC Heart Fail, 10(12), 960-962. (Read full article)
    2. Hanff TC, Kemeyou L (2021). Impaired Forced Expiratory Volume Across the Heart Failure Spectrum. Chest, 161(1), 11-12. (Read full article)
    3. Siripanthong B, Hanff TC, Levin MG, Vidula MK, Khanji MY, Nazarian S, Chahal CAA (2020). Coronavirus disease 2019 is delaying the diagnosis and management of chest pain, acute coronary syndromes, myocarditis and heart failure. Future Cardiol, 17(1), 3-6. (Read full article)
    4. Hanff TC, Birati EY (2019). Left Ventricular Assist Device as Destination Therapy: a State of the Science and Art of Long-Term Mechanical Circulatory Support. Curr Heart Fail Rep, 16(5), 168-179. (Read full article)

    Letter

    1. Edwards JJ, Edelson JB, Katcoff H, Mondal A, Lefkowitz D, Reza N, Hanff TC, Griffis H, Mazurek JA, Wald J, Owens AT, Wittlieb-Weber CA, Burstein DS, Atluri P, OConnor MJ, Goldberg LR, Zamani P, Groeneveld PW, Rossano JW, Lin KY, Birati EY (2021). Mental health disorders and emergency resource use and outcomes in ventricular assist device supported patients. [Letter to the editor]. Am Heart J, 240, 11-15. (Read full article)
    2. Hanff TC, Goldberg LR, Birati EY (2020). Venoarterial Extracorporeal Membrane Oxygenation to Heart Transplant-An Inflamed Bridge?-Reply. [Letter to the editor]. JAMA Cardiol, 6(3), 362-363. (Read full article)
    3. Hanff TC, Harhay MO, Brown TS, Cohen JB, Mohareb AM (2020). Reply to Tedeschi et al. [Letter to the editor]. Clin Infect Dis, 71(15), 901. (Read full article)
    4. Hanff TC, Harhay MO, Kimmel SE, Birati EY, Acker MA (2020). Update to an early investigation of outcomes with the new 2018 donor heart allocation system in the United States. [Letter to the editor]. J Heart Lung Transplant, 39(7), 725-726. (Read full article)
    5. Cohen JB, Hanff TC, South AM, Sparks MA, Hiremath S, Bress AP, Byrd JB, Chirinos JA (2020). Response by Cohen et al to Letter Regarding Article, "Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19". [Letter to the editor]. Circ Res, 126(12), e140-e141. (Read full article)

    Other

    1. Baran DA, Billia F, Randhawa V, Cowger JA, Barnett CM, Chih S, Ensminger S, Hernandez-Montfort J, Sinha SS, Vorovich E, Proudfoot A, Lim HS, Blumer V, Jennings DL, Reshad Garan A, Renedo MF, Hanff TC, Kanwar MK, Consensus Conference participantscollaborators (2023). Consensus statements from the International Society for Heart and Lung Transplantation consensus conference: Heart failure-related cardiogenic shock. J Heart Lung Transplant (43(2), pp. 204-216). United States. (Read full article)

  • News & Podcasts